[1] 牛晓辉. 中国骨肉瘤综合治疗现状与展望[J]. 中华解剖与临床杂志, 2019, 24(1): 1.
[2] CASTILLO-TANDAZO W, MUTSAERS AJ, WALKLEY CR. Osteosarcoma in the post genome era: preclinical models and approaches to identify tractable therapeutic targets[J]. Curr Osteoporos Rep, 2019, 17(5): 343. doi: 10.1007/s11914-019-00534-w
[3] ALLISON DC, CARNEY SC, AHLMANN ER, et al. A meta-analysis of osteosarcoma outcomes in the modern medical era[J]. Sarcoma, 2012, 2012: 704872.
[4] MISHRA S, YADAV T, RANI V. Exploring miRNA based approaches in cancer diagnostics and therapeutics[J]. Crit Rev Oncol Hematol, 2016, 98(1): 12.
[5] ZHANG W, WEI L, SHENG W, et al. miR-1225-5p functions as a tumor suppressor in osteosarcoma by targeting Sox9[J]. DNA Cell Biol, 2019, 25(1): 126.
[6] WANG S, CHEN X, ZHANG Z, et al. MicroRNA-1225-5p inhibits the development and progression of thyroid cancer via targeting sirtuin 3[J]. Pharmazie, 2019, 74(7): 423.
[7] ZHONG R, LI S, FANG K, et al. microRNA-1225 inhibit apoptosis of pancreatic cancer cells via targeting JAK1[J]. Cell Cycle, 2019, 18(9): 990. doi: 10.1080/15384101.2019.1608127
[8] SUN P, ZHANG D, HUANG H, et al. MicroRNA-1225-5p acts as a tumor-suppressor in laryngeal cancer via targeting CDC14B[J]. Biol Chem, 2019, 400(2): 237. doi: 10.1515/hsz-2018-0265
[9] 流小舟, 于沂阳, 施鑫, 等. 骨肉瘤复发患者的转归及影响长期生存的因素分析——一项基于多中心骨肉瘤复发患者的长期随访研究[J]. 中华骨科杂志, 2018, 38(18): 1089. doi: 10.3760/cma.j.issn.0253-2352.2018.18.001
[10] MONTERDE-CRUZ L, RAMIREZ-SALAZAR EG, RICO-MARTINEZ G, et al. Circulating miR-215-5p and miR-642a-5p as potential biomarker for diagnosis of osteosarcoma in Mexican population[J]. Hum Cell, 2018, 31(4): 292. doi: 10.1007/s13577-018-0214-1
[11] ROBERTS RD, LIZARDO MM, REED DR. Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group[J]. Cancer, 2019, 125(20): 3514. doi: 10.1002/cncr.32351
[12] 许国泰, 周姣丽, 郭胜, 等. miR-590-5p靶向调控STAT3基因对骨肉瘤143B细胞迁移和侵袭的影响[J]. 蚌埠医学院学报, 2017, 42(9): 1165.
[13] TOKUHISA M, ICHIKAWA Y, KOSAKA N, et al. Exosomal miRNAs from peritoneum lavage fluid as potential prognostic biomarkers of peritoneal metastasis in gastric cancer[J]. PLoS One, 2015, 10(7): e0130472. doi: 10.1371/journal.pone.0130472
[14] ZHENG H, ZHANG F, LIN X, et al. MicroRNA-1225-5p inhibits proliferation and metastasis of gastric carcinoma through repressing insulin receptor substrate-1 and activation of beta-catenin signaling[J]. Oncotarget, 2016, 7(4): 4647. doi: 10.18632/oncotarget.6615
[15] 王文剑, 于秀淳. 骨肉瘤预后影响因素的Meta分析[J]. 国际骨科学杂志, 2018, 39(1): 45. doi: 10.3969/j.issn.1673-7083.2018.01.012
[16] SIMPSON S, DUNNING MD, DE BROT S, et al. Comparative review of human and canine osteosarcoma: morphology, epidemiology, prognosis, treatment and genetics[J]. Acta Vet Scand, 2017, 59(1): 71. doi: 10.1186/s13028-017-0341-9
[17] LIU M, YANG P, MAO G, et al. Long non-coding RNA MALAT1 as a valuable biomarker for prognosis in osteosarcoma: A systematic review and meta-analysis[J]. Int J Surg, 2019, 72(1): 206.